Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab ...
AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...
Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...
Nurix advances CLL therapy with NX-5948 showing 83% response, 22.1-month PFS, $680M cash, and $3B risk-adjusted sales ...
Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple ...
Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...
Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma: Raritan, New Jersey Friday, January 16, 2026, 10:00 Hrs [ ...
Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said. AbbVie and Genmab said ...
President Dr. Valerie Fuller attended a White House event today focused on the Rural Health Transformation Program (RHTP) and ...
Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to ...
Segment 6 focuses on decision-making in second-line therapy for cGVHD, centering on the role of ruxolitinib. Dr. DeFilipp ...
Genmab (GMAB) stock slips as trial data for the company's lymphoma therapy Epkinly (epcoritamab) marketed with AbbVie (ABBV) falls short of expectations. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback